<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841201</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUNIB</org_study_id>
    <nct_id>NCT03841201</nct_id>
  </id_info>
  <brief_title>Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma</brief_title>
  <official_title>IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, open-label, single arm, multicenter phase II trial for the evaluation
      of efficacy and feasibility (as determined by safety and tolerability) of immunotherapy with
      nivolumab in combination with lenvatinib for patients with multinodular, advanced stage
      hepatocellular carcinoma in first line therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single-arm, multicenter phase II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) according to RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Number and percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability (AEs, SAEs according to NCI-CTCAE V 4.03)</measure>
    <time_frame>6 months</time_frame>
    <description>Type, incidence and severity of AEs, SAEs according to NCI-CTCAE V 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) according to iRECIST</measure>
    <time_frame>6 months</time_frame>
    <description>Number and percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) according to iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression (TTP)</measure>
    <time_frame>6 months</time_frame>
    <description>Time from the date of treatment allocation to the date of first observed disease progression (investigator assessment according to RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>Time from the date of treatment allocation to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>Time from the date of treatment allocation to the date of death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational research</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR) from lenvatinib plus nivolumab by molecular quantitation of mRNA expression of parameters like e.g. PD-1, PD-L1 and PD-L2, immune cell infiltrates (IGHM, CD3, CD8, FOXP3, CD68, CD205), chemokines (CXCL9, CXCL10, CXCL13) and invasion markers (MMP7, MMP9).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenvatinib peroral qd (8 mg for patients with body weight &lt;60kg and 12 mg for patients with body weight ≥ 60kg)
Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Study treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>iv infusion</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Study treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fully-informed written consent.

          2. Males and females ≥ 18 years of age

             *There are no data that indicate special gender distribution. Therefore patients will
             be enrolled in the study gender-independently.

          3. Unresectable, multinodular tumour, not eligible for resection or local ablation

          4. Histologically confirmed diagnosis of hepatocellular carcinoma

          5. Has a Child-Pugh Classification score ≤ 6 for assessed liver function within 7 days
             before allocation (Appendix 4: Child-Pugh Score)

          6. At least one measurable site of disease as defined by RECIST 1.1 criteria with spiral
             CT scan or MRI.

          7. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

          8. Life expectancy of at least 12 weeks.

          9. Adequate bone marrow, hepatic and renal function including the following:

               -  Haemoglobin ≥ 10.0 g/dL, absolute neutrophil count ≥ 1,500 /µL, platelets ≥70,000
                  /µL;

               -  Total bilirubin ≤ 3.0 mg/dL upper normal limit;

               -  AST (SGOT), ALT (SGPT) ≤ 5 x upper normal limit;

               -  International normalized ratio (INR) ≤1.25;

               -  Albumin ≥ 30 g/dL;

               -  Creatinine ≤ 1.5 x upper normal limit OR measured or calculated creatinine
                  clearance (according to Cockcroft-Gault) ≥30 mL/min for participant with
                  creatinine levels &gt;1.5 × institutional ULN (GFR can also be used in place of
                  creatinine or CrCl)

         10. Female patients with reproductive potential must have a negative urine or serum
             pregnancy test within 7 days prior to start of trial. Women must not be breastfeeding.

         11. If patient has concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV)
             infection, meets the following criteria:

               -  Patients with HBV or HCV infection should be monitored for viral levels during
                  study participation.

               -  Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV
                  DNA should have HBV DNA &lt; 100 IU/ml and should be managed per local treatment
                  guidelines.

             Controlled (treated) hepatitis B subjects will be allowed if they started treatment at
             the time point of enrollment into the study by the latest and treatment is continued
             during study participation and for ≥ 6 months after end of study treatment.

             - HCV patients with with advanced HCC are mostly not treated for their HCV infection.
             However, patients treated for HCV are considered suitable for inclusion if antiviral
             therapy has been completed ≥ 30 days prior to first administration of study drug.

         12. The patient is willing and able to comply with the protocol for the duration of the
             study, including hospital visits for treatment and scheduled follow-up visits and
             examinations.

         13. WOCBP must agree to follow instructions for method(s) of contraception for a period of
             30 days (duration of ovulatory cycle) plus the time required for the investigational
             drug to undergo 5 half-lives. The terminal half-lives of nivolumab is approximately 25
             days. WOCBP should use an adequate method to avoid pregnancy for approximately 5
             months (30 days plus the time required for nivolumab to undergo 5 half-lives) after
             the last dose of investigational drug.

         14. Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for a period of 90 days (duration of sperm turnover) plus
             the time required for the investigational drug to undergo 5 half-lives. The terminal
             half-lives of nivolumab is approximately 25 days. Males who are sexually active with
             WOCBP must continue contraception for approximately 7 months (90 days plus the time
             required for nivolumab to undergo 5 half-lives) after the last dose of investigational
             drug. In addition, male subjects must be willing to refrain from sperm donation during
             this time.

        Exclusion Criteria:

          1. Previous systemic therapy in the first-line setting.

          2. Patients on a liver transplantation list or with advanced liver disease as defined
             below:

               -  Encephalopathy

               -  Untreatable Ascites.

          3. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

          4. Prior organ allograft or allogeneic bone marrow transplantation.

          5. Local therapies ongoing or completed &lt;4 weeks prior to the baseline scan.

          6. Thrombotic or embolic events such as cerebrovascular accident (including transient
             ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months
             prior to the first dose of study drug with the exception of thrombosis of a segmental
             portal vein.

          7. Prior, systemic anti-cancer chemotherapy, radiotherapy administered &lt;4 weeks prior to
             study entry, endocrine- or immunotherapy or use of other investigational agents.

          8. History of (non-infectious) pneumonitis that required steroids or current pneumonitis.

          9. Major surgery within 4 weeks of starting the study. Patients must have recovered from
             effects of major surgery.

         10. Malignancies other than disease under study within 5 years prior to inclusion, with
             the exception of those with a negligible risk of metastasis or death (e.g., expected
             5-year OS &gt; 90%) treated with expected curative outcome (such as adequately treated
             carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized
             prostate cancer treated surgically with curative intent, ductal carcinoma in situ
             treated surgically with curative intent)

         11. Uncontrolled hypertension.

         12. Clinically significant cardiovascular disease.

         13. Any serious or uncontrolled medical disorder or active infection that, in the opinion
             of the investigator, may increase the risk associated with study participation, study
             drug administration, or would impair the ability of the subject to receive study drug.

         14. Proteinuria (≥2g/24h)

         15. Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or compliance with the study protocol.

         16. Subjects with a history of or current CNS metastases. A scan to confirm the absence of
             brain metastases is not required. Patients with unknown CNS metastatic status and any
             clinical signs indicative of CNS metastases are eligible if CNS metastases are
             excluded using CT and/or MRI scans.

         17. Pregnant or breast-feeding women.

         18. Immunocompromised patients, e.g. patients who are known to be serologically positive
             for human immunodeficiency virus (HIV).

         19. Subjects with active, known, or suspected autoimmune disease. Subjects with Type I
             diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only
             requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or
             alopecia) not requiring systemic treatment are permitted to enroll. For any cases of
             uncertainty, it is recommended that the medical monitor be consulted prior to signing
             informed consent.

         20. Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration. Inhaled or topical steroids, and adrenal
             replacement doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of
             active autoimmune disease.

         21. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4
             antibody, or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways.

         22. All toxicities attributed to prior anti-cancer therapy other than hearing loss,
             alopecia and fatigue must have resolved to Grade 1 (NCI CTCAE version 4.03) or
             baseline before administration of study drug.

         23. &gt; Grade 1 peripheral neuropathy according to CTCAE version 4.03

         24. Patients who have received a live vaccine within 30 days prior to enrolment.

         25. History of allergy or hypersensitivity to study drugs or any constituent of the
             products

         26. Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment.

         27. Patient who has been incarcerated or involuntarily institutionalized by court order or
             by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

         28. Patients who are unable to consent because they do not understand the nature,
             significance and implications of the clinical trial and therefore cannot form a
             rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt Vogel, MD</last_name>
    <phone>+49 176 1 532</phone>
    <phone_ext>9590</phone_ext>
    <email>vogel.arndt@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel W Mueller, PhD</last_name>
    <phone>+49 69 7601</phone>
    <phone_ext>4125</phone_ext>
    <email>mueller.daniel@ikf-khnw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Vogel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

